Genmab — Juni 2023
-
Video opdatering: Det har ikke stået stille på nyhedsfronten, når det gælder flere af de populære pharma- og biotekselskaber på ProInvestor.com. Først og fremmest om EMA's ønske om undersøgelse af kræftrisikoen i to af Novo Nordisks produkter - er der grund til at være nervøs? Nyheden smitter også af på Zealand Pharmas aktiekurs. ALK-Abellós direktør går af i kølvandet på et dårligt kvartalsregnskab. Og hvad sker der med kursen på Genmab? . https://www.proinvestor.com/boards/113379
-
Genmab slutter rigtigt pænt i USA - omregnet kurs 2616. Så heller ingrn panik over there.
-
-
Shortpositioner på danske aktier https://www.proinvestor.com/boards/113385
-
EPCORE DLBCL-1 seems fully recruited. They are extending the duratoin of the trial by 4 years. Outcomes will now be measured for 5 years instead of the intended 2 years. How should i read this? Is this a requirement by the FDA? Or are they now thinking patients could still be active on Epco after 5 years instead of 2? https://classic.clinicaltrials.gov/ct2/history/NCT04628494?B=24&A=23&C=merged#StudyPageTop
-
Case report: Successful treatment with daratumumab for pure red cell aplasia in a patient with mixed lymphoid chimerism after ABO-mismatched stem cell transplant for sickle cell disease https://www.frontiersin.org/articles/10.3389/fimmu.2023.1212007/full?utm_source=S-TWT&utm_medium=SNET&utm_campaign=ECO_FIMMU_XXXXXXXX_auto-dlvrit
-
I hope you are right @Sukkeralf . I do believe interim data can be sufficient for filing
-
$XBI Big Biotech #Outflows Return
~$894M of net outflows
This is the #second #largest week of outflows for the sector this year and marks
the 19th week of outflows out of 25 total weeks in 2023. YTD net fund flow now stands
at ~$7.2B in outflows. https://twitter.com/BiotechAnalysst/status/1672236857281716225 -
Enig Riis.Tendensen er klart i den retning.
-
TEPEZZA
(teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease (TED) https://ir.horizontherapeutics.com/news-releases/news-release-details/tepezzar-teprotumumab-approved-brazil-treatment-active-thyroid
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind